Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exforge in Turkish Hypertensive Patients
NCT02062645Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amlodipine + valsartan in essential hypertension, sponsored by Novartis. Primary endpoint: Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at 8 weeks. Started Feb 2014; status: completed.
02
Drugs
amlodipine + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02062645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062645.